Article

Dr. Kolodziej Discusses The Use of Novel Treatments in Combination Therapy

Conference|ASCO: American Society of Clinical Oncology

Michael Kolodziej, MD, National Medical Director for Oncology Strategies, Aetna, discusses the financial challenges associated with the combination of newer novel agents in breast cancer treatment.

Michael Kolodziej, MD, National Medical Director for Oncology Strategies, Aetna, discusses the financial challenges associated with the combination of newer novel agents in breast cancer treatment. He suggests that more careful healthcare spending could support the high costs, and deliver the potential benefits of these drug combinations. "This situation is not unique to breast cancer," said Kolodziej. "You can extrapolate it to just about any disease we treat these days.

This video was taken on June 1, 2013, at the ASCO Annual Meeting 2013 in Chicago, IL.

Related Videos
Katrina Ortblad, ScD, MPH, Fred Hutch Cancer Center
Michelle Hessen, OD
Douglas Flora, MD, FACCC
Bridgette J. Picou, LVN, ACLPN, The Well Project
Priscilla Tsondai, MD, MPH, IAS/CIPHER
Mia Moore, PhD, Fred Hutch Cancer Center
Steven Daniel Daveluy, MD, FAAD
Shawn Kwatra, MD, FAAD
Elizabeth Jones, MD, FAAD.
Related Content
Pediatric AD. | Image Credit: Evgeniya Primavera - stock.adobe.com
March 13th 2025

Addressing Financial Aid and Patient Independence as Part of Atopic Dermatitis Care

Cameron Santoro
Discussions centered on mitigating the financial burden of pediatric atopic dermatitis through financial aid programs and enhancing support for young patients to independently manage their condition were emphasized at this year’s 2025 American Academy of Dermatology meeting.
managed care cast logo
October 24th 2024

Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions

Brooke McCormick
On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
ART | Image credit: gamjai - stock.adobe.com
March 13th 2025

Late-Breaking Antiviral Session Features Phase 3 Results on Efficacy of Doravirine/Islatravir

Julia Bonavitacola
The combination of doravirine plus islatravir was noninferior to bictegravir/emtricitabine/tenofovir alafenamide and oral antiretroviral therapy in patients who switched to doravirine plus islatravir.
Managed Care Cast logo
April 25th 2024

Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic

Brooke McCormick
On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Different forms of ART | Image credit: jarun011 - stock.adobe.com
March 12th 2025

Long-Acting Injectable Cabotegravir Effective in Both ART, PrEP

Julia Bonavitacola
Cabotegravir was found to prevent HIV acquisition as a monotherapy pre-exposure prophylaxis (PrEP) and to treat HIV as a combination antiretroviral therapy (ART) in its long-acting injectable form.
Insurance reimbursement financial money | Image Credit: © onephoto - stock.adobe.com.jpeg
March 12th 2025

VBID, Heading Into a Third Decade, Looks to Promote Personalization and Access

Christina Mattina
Speakers at the 2025 Value-Based Insurance Design summit recapped the accomplishments made over the past 20 years in designing insurance benefits with value in mind and looked ahead to iterations to come.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo